Bioniche names new CEO
05 November, 2013 by Dylan Bushell-EmblingDr Michael Berendt has replaced Bioniche (ASX:BNC) founder Graeme McRae as the company's CEO.
Spruiking for business the UK way
04 November, 2013 by Susan WilliamsonThe UK delegation that attended the recent 2013 AusBiotech meeting is keen to develop its relationship with the Australian biotech sector.
WA biotechs pick up industry and export awards
04 November, 2013 by Dylan Bushell-EmblingClinical trials facility Linear Clinical Research, drug discovery CRO Epichem and sera supplier Serana have all won prizes during this year's Western Australian Industry and Export Awards.
Mesoblast partner cleared for phase III heart trial
04 November, 2013 by Dylan Bushell-EmblingMesoblast's partner Teva Pharmaceutical Industries has secured US FDA approval for a phase III IND trial of Mesoblast's MPCs in congestive heart failure.
Pharmaxis taking up full $42m financing deal
01 November, 2013 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has elected to receive the full US$40m investment from NovaQuest, to help fund its continuing efforts to achieve US approval for Bronchitol in cystic fibrosis.
Regeneus stem cell therapy reaches Melbourne
01 November, 2013 by Dylan Bushell-EmblingLinley Clinic Private Hospital has become the first Melbourne clinic to offer Regeneus's (ASX:RGS) HiQCell, a point-of-care cell therapy for musculoskeletal conditions.
Surgical device start-up Protego Medical launches
01 November, 2013 by Dylan Bushell-EmblingProtego Medical, a company developing a device to protect the sternum during cardiac surgery, launched yesterday with $2m in MRCF seed funding.
Hatchtech hardly a head-scratcher for investors
01 November, 2013 by Dylan Bushell-EmblingHatchtech has raised $12.6m from existing and new investors to support its phase III trials and US NDA for DeOvo, a single-dose headlice treatment.
AusBiotech 2013 national conference opens in Brisbane with industry awards
31 October, 2013Brisbane yesterday welcomed the official launch of the AusBiotech 2013 national conference - a premier event on the Australia and Asia-Pacific calendar - recognising world-class leaders in the biotechnology industry with the Janssen Industry Excellence Awards.
Nexvet secures $7m in capital raising
30 October, 2013 by Dylan Bushell-EmblingNexvet has closed an oversubscribed capital raising, taking in an extra $7m to support its veterinary biological drug development programs.
Industry body MTAA names newest board
29 October, 2013 by Dylan Bushell-EmblingMedical technology industry body MTAA has announced the appointment of three new board members, and the departure of two more who have served their maximum six-year term.
New guide launched at major life science investor event
29 October, 2013The Victorian Minister for Technology, the Hon Gordon Rich-Phillips, yesterday launched the new 'Guide for Life Science Company Directors' at the opening of Australia’s biggest biotech investment event in this part of the world to date - Australia Biotech Invest 2013.
Mesoblast close to milestone payments from Japan deal
28 October, 2013 by Dylan Bushell-EmblingA Japanese licensee to Mesoblast's MSC technology will soon file for regulatory approval in the market for a treatment for steroid-refractory GvHD.
ResMed lifts September quarter profit by 14%
28 October, 2013 by Dylan Bushell-EmblingResMed (ASX:RMD) said its revenue for the September quarter increased 5%, despite what CEO Mick Farrell called a "tough competitive product cycle".
Biotron posts early data from HIV/HCV trial
25 October, 2013 by Dylan Bushell-EmblingDuring a phase II trial, Biotron's (ASX:BIT) BIT225 has shown promise at enhancing antiviral activity in hard-to-treat HCV Genotype 3 patients undergoing the IFN/RVB treatment regimen.
